Navigation Links
Abeome Forms First Class Scientific Advisory Board
Date:9/10/2008

ATHENS, Ga., Sept. 10 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, today announced the formation of its Scientific Advisory Board (SAB) to collaborate on the development of Abeome's ovarian cancer project and to select and guide future therapeutic and diagnostic projects for the company.

The SAB will be led by scientific founder Richard Meagher, PhD, Chief Scientific Officer for Abeome, Distinguished Research Professor at the University of Georgia, and inventor of Abeome's patented monoclonal antibody technology. The SAB will consist of:

Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations as well as for her broad scientific applications of biotechnology, genomics and biomarker discovery in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases. Dr. Debouck brings 24 years of experience in directing creative science in diverse areas of research.

Jeff Boyd, PhD, Chief Scientific Officer and Sr. VP at Fox Chase Cancer Center in Philadelphia, has an international reputation as one of the leading scientists in the study of molecular genetics of women's cancers. Dr. Boyd was named Distinguished Cancer Scholar by the Georgia Cancer Coalition. His long-term research focus has studied molecular genetics of ovarian cancer with emphasis on hereditary predisposition.

Linda Matsuuchi, PhD, Associate Director of the Life Sciences Institute at the University of British Columbia, has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes, the source of antibody production.

"We are pleased to assemble such an incredibly talented team of scientists to serve on our SAB and to participate in target validation on our ovarian cancer therapeutic project. Their active participation provides Abeome with valuable expertise in pre-clinical and clinical trials, unparalleled knowledge of ovarian cancer pathology, and years of immunology experience specific to monoclonal antibody development," states Abeome CEO, Mike Wanner.

"The company will deploy its monoclonal antibody technology to rapidly develop a pipeline of therapeutic candidates in a number of cancer areas and will benefit by these individual's commitment to our mission. They join an already outstanding group of Abeome scientists, biotech-oriented Board of Directors, and scientific founder, Dr. Richard Meagher to form a team of world-class scientists to insure Abeome's future success."

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance. Its current focus is on developing a cancer therapeutic and diagnostic for ovarian cancer.

For more information on Abeome, visit http://www.abeomecorp.com.


'/>"/>
SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management
2. Neogen Forms Mexican Subsidiary
3. BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts
4. American Oriental Bioengineering Forms Science and Technology Advisory Committee
5. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
6. Agrenco Informs Sale of Biodiesel at ANP Auction
7. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
8. International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative
9. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
10. febit Forms Scientific Advisory Board
11. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... StarNet Communications ... today announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 ... desktops from Linux and Unix servers to the user’s PC over encrypted SSH. , ...
(Date:4/29/2016)... ... 30, 2016 , ... The MIT bioLogic design team has won multiple ... bacterial properties can be applied to fabric and formed into living interfaces between body ... to humidity change. The team harvested Natto cells and applied them to fabric with ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... devices used in spinal surgical procedures, today announced the completion of a significant ... proposition for current and future customers and partners. Kohlberg & Company, L.L.C. ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, joined ... Kelley, a recognized leader and mentor in the Denver area business community, shared ...
Breaking Biology Technology:
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... 9, 2016 This BCC Research report provides ... the RNA Sequencing (RNA Seq) market for the years ... tools and reagents, data analysis, and services. ... the RNA-Sequencing market such as RNA-Sequencing tools and reagents, ... factors affecting each segment and forecast their market growth, ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
Breaking Biology News(10 mins):